Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 21784889)

1.

Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?

Huot P, Fox SH, Newman-Tancredi A, Brotchie JM.

J Pharmacol Exp Ther. 2011 Oct;339(1):2-8. doi: 10.1124/jpet.111.184093. Epub 2011 Jul 22. Review.

2.

5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.

Huot P, Johnston TH, Winkelmolen L, Fox SH, Brotchie JM.

Neurobiol Aging. 2012 Jan;33(1):194.e5-15. doi: 10.1016/j.neurobiolaging.2010.04.035. Epub 2010 Jun 18.

PMID:
20561716
3.

Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.

Fox SH, Chuang R, Brotchie JM.

Prog Brain Res. 2008;172:479-94. doi: 10.1016/S0079-6123(08)00923-0. Review.

PMID:
18772047
4.

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.

Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235. Epub 2008 Oct 24.

5.

Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque.

Huot P, Johnston TH, Koprich JB, Winkelmolen L, Fox SH, Brotchie JM.

Neurobiol Aging. 2012 Jan;33(1):207.e9-19. doi: 10.1016/j.neurobiolaging.2010.09.011. Epub 2010 Nov 3.

PMID:
21051107
6.

Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.

Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM.

J Neurosci. 2011 May 11;31(19):7190-8. doi: 10.1523/JNEUROSCI.1171-11.2011.

7.

Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.

Shin E, Garcia J, Winkler C, Björklund A, Carta M.

Neurobiol Dis. 2012 Sep;47(3):393-406. doi: 10.1016/j.nbd.2012.03.038. Epub 2012 Apr 12.

PMID:
22579773
8.

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

Carta M, Carlsson T, Kirik D, Björklund A.

Brain. 2007 Jul;130(Pt 7):1819-33. Epub 2007 Apr 23.

9.
10.

GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.

Iravani MM, Costa S, Jackson MJ, Tel BC, Cannizzaro C, Pearce RK, Jenner P.

Eur J Neurosci. 2001 Feb;13(3):597-608.

PMID:
11168568
11.

New insight into the therapeutic role of 5-HT1A receptors in central nervous system disorders.

Ohno Y.

Cent Nerv Syst Agents Med Chem. 2010 Jun 1;10(2):148-57. Review.

PMID:
20518729
12.

5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis.

de Boer SF, Koolhaas JM.

Eur J Pharmacol. 2005 Dec 5;526(1-3):125-39. Epub 2005 Nov 28. Review.

PMID:
16310183
13.

What can we expect from the serotonergic side of L-DOPA?

De Deurwaerdère P, Navailles S.

Rev Neurol (Paris). 2012 Dec;168(12):927-38. doi: 10.1016/j.neurol.2012.01.585. Epub 2012 May 2. Review.

PMID:
22560009
15.

Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

Ohno Y.

CNS Neurosci Ther. 2011 Feb;17(1):58-65. doi: 10.1111/j.1755-5949.2010.00211.x. Epub 2010 Nov 21. Review.

PMID:
21091640
16.

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.

Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T.

Parkinsonism Relat Disord. 2009 Jul;15(6):445-52. doi: 10.1016/j.parkreldis.2008.11.001. Epub 2009 Feb 3.

PMID:
19196540
17.

Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.

Jenner P.

Mov Disord. 2008;23 Suppl 3:S585-98. doi: 10.1002/mds.22022. Review.

PMID:
18781676
18.

The serotonergic system in motor and non-motor manifestations of Parkinson's disease.

Huot P, Fox SH.

Exp Brain Res. 2013 Oct;230(4):463-76. doi: 10.1007/s00221-013-3621-2. Epub 2013 Jun 28. Review.

PMID:
23811734
19.

The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.

Koprich JB, Fox SH, Johnston TH, Goodman A, Le Bourdonnec B, Dolle RE, DeHaven RN, DeHaven-Hudkins DL, Little PJ, Brotchie JM.

Mov Disord. 2011 Jun;26(7):1225-33. doi: 10.1002/mds.23631. Epub 2011 Apr 4.

PMID:
21465551
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk